Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 4 de 4
1.
Hippocampus ; 27(10): 1110-1122, 2017 10.
Article En | MEDLINE | ID: mdl-28667669

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder characterized by amyloid-beta (Aß) plaques and tau neurofibrillary tangles. APPswe/PS1dE9 (APP/PS1) mice have been developed as an AD model and are characterized by plaque formation at 4-6 months of age. Here, we sought to better understand AD-related cognitive decline by characterizing various types of memory. In order to better understand how memory declines with AD, APP/PS1 mice were bred with ArcCreERT2 mice. In this line, neural ensembles activated during memory encoding can be indelibly tagged and directly compared with neural ensembles activated during memory retrieval (i.e., memory traces/engrams). We first administered a battery of tests examining depressive- and anxiety-like behaviors, as well as spatial, social, and cognitive memory to APP/PS1 × ArcCreERT2 × channelrhodopsin (ChR2)-enhanced yellow fluorescent protein (EYFP) mice. Dentate gyrus (DG) neural ensembles were then optogenetically stimulated in these mice to improve memory impairment. AD mice had the most extensive differences in fear memory, as assessed by contextual fear conditioning (CFC), which was accompanied by impaired DG memory traces. Optogenetic stimulation of DG neural ensembles representing a CFC memory increased memory retrieval in the appropriate context in AD mice when compared with control (Ctrl) mice. Moreover, optogenetic stimulation facilitated reactivation of the neural ensembles that were previously activated during memory encoding. These data suggest that activating previously learned DG memory traces can rescue cognitive impairments and point to DG manipulation as a potential target to treat memory loss commonly seen in AD.


Alzheimer Disease/physiopathology , Alzheimer Disease/therapy , Dentate Gyrus/physiopathology , Memory/physiology , Optogenetics , Aging/pathology , Aging/physiology , Aging/psychology , Alzheimer Disease/pathology , Alzheimer Disease/psychology , Amyloid beta-Protein Precursor/genetics , Amyloid beta-Protein Precursor/metabolism , Animals , Cognition/physiology , Dentate Gyrus/pathology , Disease Models, Animal , Disease Progression , Humans , Male , Memory Disorders/pathology , Memory Disorders/physiopathology , Memory Disorders/therapy , Mice, 129 Strain , Mice, Inbred C57BL , Mice, Transgenic , Neuropsychological Tests , Presenilin-1/genetics , Presenilin-1/metabolism , Social Behavior , Spatial Behavior/physiology
2.
Neuropsychopharmacology ; 41(1): 45-57, 2016 Jan.
Article En | MEDLINE | ID: mdl-26329286

Fear promotes adaptive responses to threats. However, when the level of fear is not proportional to the level of threat, maladaptive fear-related behaviors characteristic of anxiety disorders result. Post-traumatic stress disorder develops in response to a traumatic event, and patients often show sensitized reactions to mild stressors associated with the trauma. Stress-enhanced fear learning (SEFL) is a rodent model of this sensitized responding, in which exposure to a 15-shock stressor nonassociatively enhances subsequent fear conditioning training with only a single trial. We examined the role of corticosterone (CORT) in SEFL. Administration of the CORT synthesis blocker metyrapone prior to the stressor, but not at time points after, attenuated SEFL. Moreover, CORT co-administered with metyrapone rescued SEFL. However, CORT alone without the stressor was not sufficient to produce SEFL. In these same animals, we then looked for correlates of SEFL in terms of changes in excitatory receptor expression. Western blot analysis of the basolateral amygdala (BLA) revealed an increase in the GluA1 AMPA receptor subunit that correlated with SEFL. Thus, CORT is permissive to trauma-induced changes in BLA function.


Basolateral Nuclear Complex/metabolism , Fear/physiology , Stress Disorders, Post-Traumatic/metabolism , Acute Disease , Animals , Basolateral Nuclear Complex/pathology , Corticosterone/metabolism , Fear/psychology , Humans , Stress Disorders, Post-Traumatic/pathology , Stress Disorders, Post-Traumatic/psychology , Stress, Psychological/metabolism , Stress, Psychological/pathology , Stress, Psychological/psychology
3.
Biol Psychiatry ; 79(9): 776-786, 2016 May 01.
Article En | MEDLINE | ID: mdl-26037911

BACKGROUND: Stress exposure is one of the greatest risk factors for psychiatric illnesses like major depressive disorder and posttraumatic stress disorder. However, not all individuals exposed to stress develop affective disorders. Stress resilience, the ability to experience stress without developing persistent psychopathology, varies from individual to individual. Enhancing stress resilience in at-risk populations could potentially protect against stress-induced psychiatric disorders. Despite this fact, no resilience-enhancing pharmaceuticals have been identified. METHODS: Using a chronic social defeat (SD) stress model, learned helplessness (LH), and a chronic corticosterone (CORT) model in mice, we tested if ketamine could protect against depressive-like behavior. Mice were administered a single dose of saline or ketamine and then 1 week later were subjected to 2 weeks of SD, LH training, or 3 weeks of CORT. RESULTS: SD robustly and reliably induced depressive-like behavior in control mice. Mice treated with prophylactic ketamine were protected against the deleterious effects of SD in the forced swim test and in the dominant interaction test. We confirmed these effects in LH and the CORT model. In the LH model, latency to escape was increased following training, and this effect was prevented by ketamine. In the CORT model, a single dose of ketamine blocked stress-induced behavior in the forced swim test, novelty suppressed feeding paradigm, and the sucrose splash test. CONCLUSIONS: These data show that ketamine can induce persistent stress resilience and, therefore, may be useful in protecting against stress-induced disorders.


Antidepressive Agents/administration & dosage , Depression/prevention & control , Ketamine/administration & dosage , Resilience, Psychological/drug effects , Stress, Psychological/complications , Animals , Anxiety , Corticosterone/administration & dosage , Depression/etiology , Fear/drug effects , Helplessness, Learned , Male , Mice , Mice, Inbred C57BL , Social Behavior
4.
Learn Mem ; 22(9): 417-25, 2015 Sep.
Article En | MEDLINE | ID: mdl-26286652

In this review, we discuss the usefulness of the distinction between fear and anxiety. The clinical use of the labels is ambiguous, often defining one in terms of the other. We first consider what a useful, objective, and scientifically valid definition would entail and then evaluate several fear/anxiety distinctions that have been made in the neurobiological literature. A strong distinction should specify the difference in conditions that lead to fear versus anxiety. Additionally, fear and anxiety should generate distinct sets of behaviors. Ideally, the two states should be supported by distinguishable neuroanatomical circuits. Such a conceptualization would be consistent with the National Institute of Mental Health's Research Domain Criteria (RDoc). The majority of neurobiological approaches to the fear versus anxiety distinction fail to differentiate the two states in terms of behavior, often using the exact same behavioral measures as indicators. Of the two that do, only Predatory Imminence Theory provides a distinction both in terms of cause and effect. Indeed, that approach provides a ready distinction of anxiety, fear, and panic in terms of both antecedent conditions and response selection rules. Additionally, it appeals to distinct neural circuits to generate these modes of action.


Anxiety/physiopathology , Brain/physiopathology , Fear/physiology , Animals , Humans , Neural Pathways/physiopathology
...